ClinicalTrials.gg
Active, not recruitingNCT07421739Updated Oct 22, 2026

Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

An observational study in Choroidal Melanoma, Indeterminate Lesions and Uveal Melanoma, sponsored by Aura Biosciences. Active, not recruiting at 1 site in Australia. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Aura Biosciences · Observational

How we know

Updated Oct 22, 2026Now Active, not recruitingPrimary outcomes revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
15
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Uveal Melanoma with a site in Australia — 8 open to participants now, 15 under way, 5 of them phase 3. Uveal Melanoma · Australia.

Started
2025
with 3 others
Observational
2 of 22
none open now
Primary completion
2028-08
later than 10 of 14 live
Registered
21st of 22
by date
Lead sponsor
2 of 22
Aura Biosciences

Among the 22 studies in Uveal Melanoma with a site in Australia, this one is one of 4 that started in 2025, is one of 2 observational ones, reaches primary completion later than 10 of the 14 other live ones, and was the 21st registered.

Uveal Melanoma

281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.

Browse Uveal Melanoma studies →

Open to participants now

8 of the 22 studies in Uveal Melanoma with a site in Australia are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 43 Uveal Melanoma studies recruiting now, 36 (84%) set no upper age limit and 4 (9%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Uveal Melanoma with a site in Australia, or all of them as a file.
02

Study summary

To assess subject-centric evidence of QoL outcomes in a subset of subjects enrolled in the global Phase 3 AU-011-301 clinical trial.

Read the detailed description

The AU-011-404 study complements the AU-011-301 clinical trial and aims to identify the broader impact of bel-sar treatment on subjects' daily lives and overall well-being through the collection of PROs. This noninterventional PRO study will provide valuable insights of treatment impact by capturing subject perspective on aspects including symptom management, functional status, and overall health-related quality of life (HRQOL).

The sites will direct interested participants to the study via a unique URL. Upon accessing the URL, participants will be asked to review/sign an informed consent document (ICD). Alternatively, subjects may review and sign a paper version of the informed consent document. Eligible participants will then be asked to answer custom survey questions followed by the EORTC QLQ-C30 and the EORTC QLQ-OPT30 questionnaires at required visits for up to 24 months.

03

Conditions studied

  • Choroidal Melanoma
  • Indeterminate Lesions
  • Uveal Melanoma
  • Ocular Melanoma

Keywords

  • Uveal Melanoma
  • Eye Cancer
  • Ocular Melanoma
  • Choroidal Melanoma
04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participating in Aura's Phase 3 CoMpass trial.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have enrolled in the Aura-sponsored clinical trial AU-011-301.

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
15 participants (estimated)
Patient registry
No

Groups and cohorts

  • No Intervention

    Observational

    Other: Non-interventional, digital, patient-reported, study

Interventions

  • OtherNon-interventional, digital, patient-reported, study

    Surveys will be collected at the following CoMpass trial visits. Scheduled visits: Visit 2 Visit 8 Visit 19 Visit 20 Visit 22 Visit 25 Visit 26 Visit 27 Visit 28 Visit 29 And any SOC (Standard of care) Visit

06

What researchers measure

Primary outcomes

  1. Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Group Core Questionnaire (EORTC )QLQ-C30 scores at weeks 65 and 104.

    Change from baseline in EORTC QLQ-C30 scores at weeks 65 and 104 assesses the impact of disease and treatment on the quality of life of patients with cancer. For the minimum and maximum values: All of the scales and single-item measures range in score from 0 to 100. For whether higher scores mean a better or worse outcome: A high-scale score represents a higher response level. Hence high scores for a functional scale represent a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems (A positive change from baseline in functional scales and global health status indicates improvement, while a negative change in symptom scales indicates symptom improvement).

    Time frame: 24 months

Secondary outcomes

  1. Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Group Questionnaire, Ophthalmic Module (EORTC) QLQ-OPT30 scores at weeks 65 and 104.

    Change from baseline in EORTC QLQ-OPT30 scores at weeks 65 and 104 assesses the impact of disease and treatment on the quality of life of patients with ophthalmic cancer specifically. For whether higher scores mean a better or worse outcome: A high-scale score represents a higher response level. Hence high scores for a functional scale represent a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems (A positive change from baseline in functional scales and global health status indicates improvement, while a negative change in symptom scales indicates symptom improvement).

    Time frame: 24 months

07

Study locations

1 site
  • Eye Research Australia
    East Melbourne, Victoria 3002, Australia
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Aug 2028, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
Feb 19, 2026
StartActual
Nov 12, 2025
Primary completionEst.
Aug 15, 2028
CompletionEst.
Aug 15, 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 15, 2026
Eligibility
1 inclusion criterion removed
What changed in the criteria
Inclusion criteria
  • RemovedAccess to a connected device (i.e., smartphone, laptop, or tablet)
Oct 15, 2026
Interventions
Changed Non-interventional, digital, patient-reported, real-world study→Non-interventional, digital, patient-reported, study
Oct 15, 2026
Primary outcomes
Revised in 2 updates
What changed on Oct 15, 2026
  • EditedChange from baseline in EORTC QLQ-C30 scores at month 15weeks 65 and 24104.Time frame: 24 months
What changed on Oct 22, 2026
  • EditedChange from baseline in European Organization for Research and Treatment of Cancer Quality of Life Group Core Questionnaire (EORTC )QLQ-C30 scores at weeks 65 and 104.Time frame: 24 months
across 2 updates, Oct 15, 2026 – Oct 22, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 15, 2026
  • EditedChange from baseline in EORTC QLQ-OPT30 scores at months 15weeks 65 and 24104.Time frame: 24 months
What changed on Oct 22, 2026
  • EditedChange from baseline in European Organization for Research and Treatment of Cancer Quality of Life Group Questionnaire, Ophthalmic Module (EORTC) QLQ-OPT30 scores at weeks 65 and 104.Time frame: 24 months
across 2 updates, Oct 15, 2026 – Oct 22, 2026
Show all 2 updates
  1. Oct 22, 2026
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange from baseline in European Organization for Research and Treatment of Cancer Quality of Life Group Core Questionnaire (EORTC )QLQ-C30 scores at weeks 65 and 104.Time frame: 24 months
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedChange from baseline in European Organization for Research and Treatment of Cancer Quality of Life Group Questionnaire, Ophthalmic Module (EORTC) QLQ-OPT30 scores at weeks 65 and 104.Time frame: 24 months
  2. Oct 15, 2026
    Recruiting→Active, not recruiting
    Eligibility 1 inclusion criterion removed
    What changed in the criteria
    Inclusion criteria
    • RemovedAccess to a connected device (i.e., smartphone, laptop, or tablet)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange from baseline in EORTC QLQ-C30 scores at month 15weeks 65 and 24104.Time frame: 24 months
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedChange from baseline in EORTC QLQ-OPT30 scores at months 15weeks 65 and 24104.Time frame: 24 months
    Interventions Changed Non-interventional, digital, patient-reported, real-world study→Non-interventional, digital, patient-reported, study
    + 4 other changes: verification date, description, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07421739
Lead sponsor
Aura Biosciences
Collaborators
Vitaccess Ltd
Responsible party
Sponsor
First posted
Feb 19, 2026
Start date
Nov 12, 2025
Primary completion
Aug 15, 2028 (estimated)
Completion
Aug 15, 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Study Director
study director · Aura Biosciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion